Unknown

Dataset Information

0

Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.

ABSTRACT: This study characterized the pharmacokinetics of novel 100-mg levofloxacin dispersible tablets in 24 children aged <5?years who had household multidrug-resistant tuberculosus (MDR-TB) exposure. The current data were pooled with previously published data from children (n?=?109) with MDR-TB receiving adult (250-mg) levofloxacin tablets, using nonlinear mixed-effects modelling. The adult tablets had 41% lower bioavailability than the novel dispersible tablets, resulting in much higher exposures with the dispersible tablets with the same dose.

SUBMITTER: Garcia-Prats AJ 

PROVIDER: S-EPMC6437514 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.

Garcia-Prats Anthony J AJ   Purchase Susan E SE   Osman Muhammad M   Draper Heather R HR   Schaaf H Simon HS   Wiesner Lubbe L   Denti Paolo P   Hesseling Anneke C AC  

Antimicrobial agents and chemotherapy 20190327 4

This study characterized the pharmacokinetics of novel 100-mg levofloxacin dispersible tablets in 24 children aged <5 years who had household multidrug-resistant tuberculosus (MDR-TB) exposure. The current data were pooled with previously published data from children (<i>n</i> = 109) with MDR-TB receiving adult (250-mg) levofloxacin tablets, using nonlinear mixed-effects modelling. The adult tablets had 41% lower bioavailability than the novel dispersible tablets, resulting in much higher exposu  ...[more]

Similar Datasets

Unknown Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
| S-EPMC6260169 | biostudies-literature
Unknown Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.
| S-EPMC5527618 | biostudies-literature
Unknown Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
| S-EPMC5786780 | biostudies-literature
Unknown Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
| S-EPMC6904296 | biostudies-literature
Unknown Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
| S-EPMC5117358 | biostudies-literature
Unknown Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.
| S-EPMC4366580 | biostudies-literature
Unknown Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
| S-EPMC6490911 | biostudies-literature
Unknown Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.
| S-EPMC6233673 | biostudies-literature
Unknown d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
| S-EPMC6260153 | biostudies-literature
Unknown Evaluation of Marbofloxacin in Beagle Dogs After Oral Dosing: Preclinical Safety Evaluation and Comparative Pharmacokinetics of Two Different Tablets.
| S-EPMC5903334 | biostudies-other